A META-ANALYSIS OF THE EFFECTS OF DEXMEDETOMIDINE ON POSTOPERATIVE CELLULAR IMMUNE FUNCTION IN PATIENTS WITH MALIGNANT TUMORS

Abstract

Objective: Comprehensively assess the impact of dexmedetomidine on cellular immune response following surgery in individuals with aggressive tumors. Methods: The research on dexmedetomidine's effects on patients with malignant tumors' postoperative cellular immune function in CNKI, Wanfang, PubMed, Ovid, MEDLINE and other databases were searched by computer, and domestic and foreign journals related to anesthesia were searched manually, and the retrieval period was October 2022. According to Jadad criteria, the included literatures' quality and bias risk were assessed, and then Revman software was used to do a meta-analysis. Results: The quality of the six included literatures was higher, mainly published from 2012 to 2022. The results of forest graph showed that the diamond graphic was located on the right side of the midline, demonstrating that, 24 hours after surgery, the dexmedetomidine team's level of CD3+ was higher than the controlling team's, and that the disparity was statistic meaningful [RR = 1.76, 95% CI (1.10 ~ 2.34), P < 0.05]. 24 hours after the procedure, the dexmedetomidine group's CD4 + level was higher than the controlling team's, and the disparity was statistic meaningful [RR = 1.65, 95% CI (1.21-2.65), P < 0.05]. 24 hours after the surgery, the level of CD8 + in the dexmedetomidine team was lower than that in the controlling team, and the disparity was statistically meaningful [RR = 1.23, 95% CI (1.08-2.11), P < 0.05]. 24 hours after surgery, the dexmedetomidine team had a higher CD4+/CD8+ ratio than the controlling team, and this disparity was statistic meaningful [RR = 1.48, 95% CI (1.13 ~ 2.67), P < 0.05]. 24 hours after surgery, the dexmedetomidine team had larger amounts of NK cells than the controlling team, and this distinction was statistically meaningful [RR = 1.11, 95% CI (0.98 ~ 2.01), P < 0.05]. Conclusion: Dexmedetomidine has a substantial impact on client prognosis and can greatly enhance postoperative immune function in clients with malignant tumors. It also offers fresh evidence for increasing client immune function suppression. Although its precise mode of action is still not completely understood, we will include a large sample size, multi-center clinical study to confirm it in the future research.